NotizieAssistito da IA

Cognizant Achieves Global Elite Partner Status with ServiceNow

Cognizant earns Global Elite status with ServiceNow, highlighting its AI-driven solutions and client success.

Mrudula Kulkarni
Di Mrudula Kulkarni
Caporedattore - Pharma Now
31 gen 2025Updated Jun 26, 2025 · 2 min di lettura
Cognizant Achieves Global Elite Partner Status with ServiceNow
Giornalismo assistito da IA
Reviewed by Mrudula Kulkarni, Caporedattore - Pharma Now

Cognizant has reached a significant milestone in its partnership with ServiceNow, earning the prestigious Global Elite status—the highest level of recognition in the ServiceNow Partner Program. With only six partners worldwide achieving this distinction, Cognizant’s elevation underscores its expertise in AI-powered solutions, workflow transformation, and customer success. The achievement is a testament to Cognizant’s investment in innovation, its deep industry knowledge, and its ability to drive business value across the ServiceNow ecosystem.

The Cognizant ServiceNow Business Group has played a crucial role in this success, leveraging AI, automation, and strategic partnerships to develop industry-specific solutions. "We are honored to be recognized as a Global Elite partner by ServiceNow and remain committed to delivering transformative solutions for our clients," said Sriramkumar Kumaresan, Cognizant’s global head of Cloud, Infrastructure, and Security. ServiceNow leaders also praised Cognizant’s ability to enhance workflows, streamline data integration, and create seamless enterprise experiences. As Cognizant continues expanding its capabilities, the company is well-positioned to drive the next wave of digital transformation in collaboration with ServiceNow.

ArgomentiNotizie
Mrudula Kulkarni
Written by
Mrudula Kulkarni
Caporedattore - Pharma Now

My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.



Discussion

Caricamento della discussione…

Altro da Pharma News

Tutti gli articoli →